Back

The relevant role of frailty in patients with transthyretin amyloidosis cardiomyopathy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure management in specific populations Comorbidities ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Beatrice Dal Passo

University Hospital of Ferrara, Ferrara (Italy)

9 More presentations in this session

Presentation thumbnail
Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population
Doctor J. Noiri (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Phenotypes of heart failure with preserved ejection fraction and effect of sodium-glucose cotransporter 2 inhibitors treatment
Doctor A. Sezaki (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Role of comorbidities and weight variations in the survival of diabetic patients with heart failure
Professor O. Hanon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease
Doctor D. Dela Cruz (Metro Manila, PH)
Abstract Slides Video
Presentation thumbnail
The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a systematic review
Doctor M. Hunjul (Nablus, PS)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure management in specific populations

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Frailty and associated outcomes in patients with transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
Multiparametric assessment of frailty in transthyretin amyloidosis cardiomyopathy and its correlation with prognostic staying scores.
thumbnail
Congress Presentation
Beyond age - A prospective cohort study on the impact of frailty, malnutrition and disability on management and survival in transthyretin cardiac amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources